StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Neurocrine Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Neurocrine Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was $898.10M, up 58.3% year over year. For fiscal 2025 it was $782.70M, up 31.5% from the year before. The highest annual figure on record is $782.70M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$782.70M+31.5%
FY2024Dec 31, 2024$595.40M+52.7%
FY2023Dec 31, 2023$389.90M+14.9%
FY2022Dec 31, 2022$339.40M+32.3%
FY2021Dec 31, 2021$256.50M+12.3%
FY2020Dec 31, 2020$228.50M+55.4%
FY2019Dec 31, 2019$147.00M+45.0%
FY2018Dec 31, 2018$101.40M–
FY2017Dec 31, 2017-$94.33M–
FY2016Dec 31, 2016-$106.18M–
FY2015Dec 31, 2015-$38.00M–
FY2014Dec 31, 2014-$47.14M–
FY2013Dec 31, 2013-$29.61M–
FY2012Dec 31, 2012-$35.29M–
FY2011Dec 31, 2011-$698.00K-101.4%
FY2010Dec 31, 2010$49.94M–
FY2009Dec 31, 2009-$53.10M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$136.40M+33.7%
Q1 FY2026Mar 31, 2026$145.80M+125.0%
Q4 FY2025Dec 31, 2025$388.40M+60.2%
Q3 FY2025Sep 30, 2025$227.50M+44.0%
Q2 FY2025Jun 30, 2025$102.00M+57.9%
Q1 FY2025Mar 31, 2025$64.80M-50.3%
Q4 FY2024Dec 31, 2024$242.50M+96.4%
Q3 FY2024Sep 30, 2024$158.00M-25.5%
Q2 FY2024Jun 30, 2024$64.60M-64.0%
Q1 FY2024Mar 31, 2024$130.30M–
Q4 FY2023Dec 31, 2023$123.50M-13.6%
Q3 FY2023Sep 30, 2023$212.00M+114.6%
Q2 FY2023Jun 30, 2023$179.60M+30.1%
Q1 FY2023Mar 31, 2023-$125.20M–
Q4 FY2022Dec 31, 2022$143.00M+3304.8%
Q3 FY2022Sep 30, 2022$98.80M+59.9%
Q2 FY2022Jun 30, 2022$138.10M+33.8%
Q1 FY2022Mar 31, 2022-$40.50M-146.4%
Q4 FY2021Dec 31, 2021$4.20M-95.6%
Q3 FY2021Sep 30, 2021$61.80M–
Q2 FY2021Jun 30, 2021$103.20M-13.2%
Q1 FY2021Mar 31, 2021$87.30M+145.9%
Q4 FY2020Dec 31, 2020$94.50M-3.1%
Q3 FY2020Sep 30, 2020-$20.40M-120.9%
Q2 FY2020Jun 30, 2020$118.90M+85.2%
Q1 FY2020Mar 31, 2020$35.50M–
Q4 FY2019Dec 31, 2019$97.50M+93.1%
Q3 FY2019Sep 30, 2019$97.80M+41.9%
Q2 FY2019Jun 30, 2019$64.20M+213.5%
Q1 FY2019Mar 31, 2019-$112.50M–
Q4 FY2018Dec 31, 2018$50.49M+24.4%
Q3 FY2018Sep 30, 2018$68.92M–
Q2 FY2018Jun 30, 2018$20.48M–
Q1 FY2018Mar 31, 2018-$38.49M–
Q4 FY2017Dec 31, 2017$40.58M–
Q3 FY2017Sep 30, 2017-$9.31M–
Q2 FY2017Jun 30, 2017-$48.24M–
Q1 FY2017Mar 31, 2017-$77.36M–
Q4 FY2016Dec 31, 2016-$31.63M–
Q3 FY2016Sep 30, 2016-$31.01M–

More Neurocrine Biosciences figures

See a number that looks wrong?